Oragenics (NYSEAMERICAN:OGEN) Issues Quarterly Earnings Results

Oragenics (NYSEAMERICAN:OGEN) released its quarterly earnings results on Friday. The company reported ($0.51) earnings per share (EPS) for the quarter, FiscalAI reports.

Oragenics Stock Down 2.6%

Shares of OGEN traded down $0.02 during midday trading on Friday, hitting $0.60. The company had a trading volume of 60,181 shares, compared to its average volume of 53,437. The company’s 50 day moving average price is $0.70 and its 200 day moving average price is $0.85. The stock has a market cap of $2.59 million, a price-to-earnings ratio of -0.05 and a beta of 1.26. Oragenics has a 52 week low of $0.50 and a 52 week high of $9.60.

Institutional Investors Weigh In On Oragenics

Several hedge funds and other institutional investors have recently modified their holdings of the stock. XTX Topco Ltd bought a new stake in shares of Oragenics in the 4th quarter worth about $26,000. DRW Securities LLC increased its position in shares of Oragenics by 82.4% in the 4th quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock worth $88,000 after purchasing an additional 50,900 shares during the last quarter. Sabby Management LLC bought a new stake in shares of Oragenics in the 3rd quarter worth about $77,000. Finally, Bank of America Corp DE increased its position in shares of Oragenics by 7,374.0% in the 2nd quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock worth $59,000 after purchasing an additional 15,338 shares during the last quarter. Institutional investors own 18.71% of the company’s stock.

Oragenics Company Profile

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.